Why Rasagiline recommends patients to eat as little as possible and analysis of the reasons

Rasagiline (Rasagiline) is a monoamine oxidase B (MAO-B) inhibitor. It is mainly used for the treatment of Parkinson's disease. It can inhibit the degradation of dopamine and increase the level of dopamine in the brain, thereby improving motor symptoms. Although its efficacy is clear, during clinical use, doctors usually recommend that patients eat as little as possible or control their dietary intake, mainly for the purpose of reducing drug side effects and optimizing drug efficacy.

Rasagiline may interact with tyramine found in certain foods. Tyramine is mainly found in certain fermented foods, aged cheeses, cured meats and red wine. High-dose intake may cause a sudden increase in blood pressure or the "cheese effect". Although rasagiline is less sensitive to tyramine than non-selective MAO inhibitors, caution is needed as controlling food intake can help reduce unintended hypertension and cardiovascular risk.

Excessive eating or eating too many high-protein and high-fat foods at one time may affect drug absorption or increase gastrointestinal burden. Rasagiline needs to be fully absorbed in the intestines to be effective after oral administration. Overeating can easily cause nausea, bloating or indigestion, affecting the efficacy of the drug. Moderate and regular meals not only contribute to stable drug absorption, but can also reduce gastrointestinal discomfort and improve patients' drug tolerance.

Proper diet can also help manage common complications of Parkinson's disease, such as constipation, weight gain, or blood sugar fluctuations. If patients overeat, especially high-sugar and high-fat foods, it may lead to blood sugar fluctuations and weight gain, which indirectly affects exercise ability and quality of life. At the same time, eating a small amount regularly helps the drug to have a more stable effect, allowing rasagiline to play its best role in delaying the progression of symptoms and improving daily motor functions.

In short, it is recommended that patients eat as little as possible or control their dietary intake while using rasagiline, mainly to reduce the risk of drug-food interaction, reduce gastrointestinal discomfort, ensure drug absorption and stable efficacy, and also help control complications related to Parkinson's disease. This medication and dietary principle should be combined with the guidance of a doctor and adjusted according to individual circumstances.

Reference materials:https://www.drugs.com/